Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Ann Surg Oncol. 2023 Mar;30(3):1302-1304. doi: 10.1245/s10434-022-12906-1. Epub 2022 Dec 6.

Authors

Carrie E Ryan¹, Areeba Saif¹, Flavio Rocha², Philip Philip³, Jonathan M Hernandez⁴, Syed Ahmad⁵, Heloisa Soares⁵

Affiliations

¹ Surgical Oncology Program, National Institutes of Health, National Cancer Institute, Bethesda, USA.
² Surgical Oncology, Oregon Health and Science University, Portland, USA.
³ Wayne State University, Detroit, USA.
⁴ Surgical Oncology Program, National Institutes of Health, National Cancer Institute, Bethesda, USA. jonathan.hernandez@nih.gov.
⁵ University of Cincinnati School of Medicine, Cincinnati, USA.

PMID: 36474095
DOI: 10.1245/s10434-022-12906-1

No abstract available

Publication types

Letter

MeSH terms

Humans
Neuroendocrine Tumors* / drug therapy
Neuroendocrine Tumors* / pathology
Neuroendocrine Tumors* / surgery
Pancreatectomy
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / pathology
Pancreatic Neoplasms* / surgery

Grants and funding

U10 CA180819/CA/NCI NIH HHS/United States